30,471 Shares in Pliant Therapeutics, Inc. (NASDAQ:PLRX) Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd bought a new position in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 30,471 shares of the company’s stock, valued at approximately $342,000. Y Intercept Hong Kong Ltd owned about 0.05% of Pliant Therapeutics at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. Summit Securities Group LLC acquired a new position in shares of Pliant Therapeutics during the 2nd quarter valued at about $59,000. Atria Investments Inc bought a new stake in Pliant Therapeutics during the third quarter worth approximately $112,000. Deerfield Management Company L.P. Series C acquired a new position in Pliant Therapeutics during the second quarter valued at approximately $126,000. China Universal Asset Management Co. Ltd. grew its holdings in Pliant Therapeutics by 65.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,694 shares of the company’s stock valued at $131,000 after purchasing an additional 4,607 shares during the last quarter. Finally, Intech Investment Management LLC bought a new position in shares of Pliant Therapeutics in the third quarter valued at approximately $145,000. 97.30% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

PLRX has been the topic of a number of research analyst reports. Leerink Partners initiated coverage on shares of Pliant Therapeutics in a research note on Monday, September 9th. They issued an “outperform” rating and a $33.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price target on shares of Pliant Therapeutics in a research report on Friday, November 8th. Finally, Leerink Partnrs raised Pliant Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pliant Therapeutics presently has an average rating of “Buy” and a consensus target price of $40.50.

Pliant Therapeutics Trading Up 4.7 %

Shares of PLRX opened at $14.37 on Wednesday. The stock’s 50-day moving average price is $14.00 and its 200 day moving average price is $12.80. The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $874.47 million, a price-to-earnings ratio of -4.30 and a beta of 1.05. Pliant Therapeutics, Inc. has a 12-month low of $10.22 and a 12-month high of $19.62.

Pliant Therapeutics Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.